<?xml version="1.0" encoding="UTF-8"?>
<document id="DDI-DrugBank.d194">
    <sentence id="DDI-DrugBank.d194.s0" text="Caution should be exercised when administering ETOPOPHOS with drugs that are known to inhibit phosphatase activities (e.g., levamisole hydrochloride).">
        <entity id="DDI-DrugBank.d194.s0.e0" charOffset="47-55"
            type="brand" text="ETOPOPHOS"/>
        <entity id="DDI-DrugBank.d194.s0.e1" charOffset="124-147"
            type="drug" text="levamisole hydrochloride"/>
        <ddi id="DDI-DrugBank.d194.s0.d0" e1="DDI-DrugBank.d194.s0.e0"
            e2="DDI-DrugBank.d194.s0.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d194.s1" text="High-dose cyclosporin A resulting in concentrations above 2000 ng/mL administered with oral etoposide has led to an 80% increase in etoposide exposure with a 38% decrease in total body clearance of etoposide compared to etoposide alone.">
        <entity id="DDI-DrugBank.d194.s1.e0" charOffset="10-22"
            type="drug" text="cyclosporin A"/>
        <entity id="DDI-DrugBank.d194.s1.e1" charOffset="92-100"
            type="drug" text="etoposide"/>
        <entity id="DDI-DrugBank.d194.s1.e2" charOffset="132-140"
            type="drug" text="etoposide"/>
        <entity id="DDI-DrugBank.d194.s1.e3" charOffset="198-206"
            type="drug" text="etoposide"/>
        <entity id="DDI-DrugBank.d194.s1.e4" charOffset="220-228"
            type="drug" text="etoposide"/>
        <ddi id="DDI-DrugBank.d194.s1.d0" e1="DDI-DrugBank.d194.s1.e0"
            e2="DDI-DrugBank.d194.s1.e1" type="mechanism"/>
    </sentence>
</document>
